HEXAXIM

Nazione: Israele

Lingua: inglese

Fonte: Ministry of Health

Principio attivo:

DIPHTHERIA TOXOID; FILAMENTOUS HAEMAGGLUTININ (FHA); HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE; HEPATITIS B VACCINES; PERTUSSIS TOXOID (PT); POLIOVIRUS TYPE 1 INACTIVATED; POLIOVIRUS TYPE 2 INACTIVATED; POLIOVIRUS TYPE 3 INACTIVATED; TETANUS PROTEIN CONJUGATE; TETANUS TOXOID

Commercializzato da:

SANOFI ISRAEL LTD

Codice ATC:

J07CA09

Forma farmaceutica:

SUSPENSION FOR INJECTION

Composizione:

DIPHTHERIA TOXOID; TETANUS PROTEIN CONJUGATE 22 - 36 MCG / 0.5 ML; HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE 12 MCG / 0.5 ML; HEPATITIS B VACCINES 10 MCG / 0.5 ML; POLIOVIRUS TYPE 3 INACTIVATED 32 DU / 0.5 ML; POLIOVIRUS TYPE 2 INACTIVATED 8 DU / 0.5 ML; POLIOVIRUS TYPE 1 INACTIVATED 40 DU / 0.5 ML; FILAMENTOUS HAEMAGGLUTININ (FHA) 25 MCG / 0.5 ML; PERTUSSIS TOXOID (PT) 25 MCG / 0.5 ML; TETANUS TOXOID

Via di somministrazione:

I.M

Tipo di ricetta:

Required

Prodotto da:

SANOFI PASTEUR, FRANCE

Area terapeutica:

DIPHTHERIA-HEMOPHILUS INFLUENZAE B-PERTUSSIS-POLIOMYELITIS-TETANUS-HEPATITIS B

Indicazioni terapeutiche:

Hexaxim (DTaP-IPV-HB-Hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks to 24 months of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenza type b (Hib).The use of this vaccine should be in accordance with official recommendations.

Data dell'autorizzazione:

2023-10-31